Cardinal Health Extends CVS Deal, Confirms FY27 EPS

Cardinal Health announced an extension of its CVS distribution agreement to 2032 and concurrently reaffirmed FY27 EPS guidance. The update is narrow in scope: it preserves an existing customer relationship and confirms management's current earnings outlook for FY27. Context from recent reported results shows the company's revenue remains highly concentrated in its Pharmaceutical and Specialty Solutions segment, which accounted for $60,669 million (92.4% of total segment revenue) in Q2 FY2026 (period ended Dec. 31, 2025). Year-over-year segment growth in Q2 FY2026 was: Pharma +19%, Global Medical Products and Distribution (GMPD) +3%, and Other +34% (Total segment revenue $65,652 million). Investors evaluating the CVS extension should weigh that Pharma distribution is the dominant revenue driver while GMPD and Other are smaller contributors. Key risk exposures remain unchanged by this announcement and are relevant to interpreting the reaffirmed FY27 EPS: ongoing opioid litigation (net charges/(recoveries) of -$18 million in Q2 FY2026 and -$185 million for FY2025), product liability litigation tied to prior agreements, tariff-related supply-cost risks, and concentration from large customer contracts (for example, the expiration of OptumRx contracts in June 2024 previously represented ~17% of FY2024 revenue). Macro and operational volatility—such as generics launch timing, GLP-1 demand swings, and declining COVID vaccine distribution—continue to affect profit and cash-flow sensitivity. Balance sheet and strategy context: management has pursued acquisitive expansion into MSO and at‑home solutions (notable deals include Solaris Health, ADS, GIA and ION) while maintaining liquidity (reported cash of $4.6 billion in Q1 FY2026). Investors should consider the CVS extension alongside integration and reimbursement risks tied to the company's higher-margin services strategy, and recent financing trends that have increased interest expense (reported net interest of $80 million in Q1 FY2026 versus $32 million previously).